他汀类药物对慢性阻塞性肺疾病治疗的潜在益处  

Potential benefits of statins in the treatment of chronic obstructive pulmonary disease

作　　者：龚益[1] 万欢英[1] 

机构地区：[1]上海交通大学医学院附属瑞金医院呼吸科,上海200025

出　　处：《世界临床药物》2011年第1期12-16,共5页World Clinical Drug

基　　金："十一五"国家科技支撑计划(项目编号2008BAI52B00)

摘　　要：他汀类药物有望成为继吸入型糖皮质激素后又一具有预防与治疗慢性阻塞性肺疾病(COPD)作用的药物。该类药物具有很强的针对肺部和血管的抗炎作用,可降低COPD患者的发病率和死亡率,延缓一秒钟用力呼气量(FEV_1)的下降,并可降低肺癌的发生率。目前以单纯的"健康用户效应"尚不能完全解释他汀类药物对COPD患者的益处。本文综述其潜在的临床益处。Besides inhaled corticosteroids, statins is likely to be another class of drugs for the treatment and prevention of chronic obstructive pulmonary disease （COPD）. Statins is of strong anti-inflammatory effects on the lungs and arteries. It can reduce the morbidity and mortality of COPD, suspend the decline of forced expiratory volume in 1^st second （FEV1） and reduce the incidence of lung cancer. So called ＂healthy user effect＂ is not able to explain the observed benefits of statins in COPD patients completely. This review summarizes potential benefits about it in clinic.

关 键 词：慢性阻塞性肺疾病 他汀类药物 潜在益处 

分 类 号：R972.6[医药卫生—药品] R563.9[医药卫生—药学]